Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WRN | Q14191 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038096 | 1.00 | WRN (0.49) | WRNMAPTALDH1A1ENPP2BACE1 | |
| SCHEMBL31500029 | 0.94 | WRN (0.47) | WRNMAPTALDH1A1ENPP2BACE1 | |
| SCHEMBL30039173 | 0.94 | WRN (0.45) | WRNMAPTALDH1A1ENPP2BACE1 | |
| SCHEMBL31057730 | 0.93 | WRN (0.55) | WRNMAPTALDH1A1BACE1P2RX7 | |
| SCHEMBL25036809 | 0.93 | WRN (0.55) | WRNMAPTALDH1A1BACE1P2RX7 | |
| SCHEMBL25037237 | 0.93 | WRN (0.43) | WRNMAPTALDH1A1ENPP2BACE1 | |
| SCHEMBL31499631 | 0.93 | WRN (0.47) | WRNMAPTBACE1P2RX7TP53 | |
| SCHEMBL30039150 | 0.92 | WRN (0.48) | WRNMAPTALDH1A1ENPP2ESR2 | |
| SCHEMBL31499590 | 0.91 | WRN (0.53) | WRNMAPTALDH1A1BACE1P2RX7 | |
| SCHEMBL25036564 | 0.90 | WRN (0.48) | WRNMAPTALDH1A1ENPP2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | WRN 1829/4885MAPT 2519/4885ALDH1A1 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.